Dr. Reddy's Laboratories' CEO Discusses Q3 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories (RDY)

Q3 2012 Earnings Call

February 03, 2012 8:00 am ET


Kedar Upadhye - Former Director

Gunupati Venkateswara Prasad - Executive Vice Chairman, Chief Executive Officer, Member of Management Council, Chairman of Investment Committee, Member of Strategy Committee, Member of Shareholders Grievance Committee and Member of Management Committee

Umang Vohra - Chief Financial Officer, Chief Compliance officer, Senior Vice President and Member of Management Council

Kallam Satish Reddy - Managing Director, Chief Operating Officer, Executive Director, Member of the Management Council, Chairman of Management Committee, Member of Shareholders Grievance Committee, Member of Investment Committee and Member of Strategy Committee


Ashwin Agarwal

Nimish Mehta - MP Advisors

Manoj Garg - Edelweiss Capital Ltd., Research Division

Sonal Gupta - UBS Investment Bank, Research Division

Bino Pathiparampil - IIFL Research

Nitin Agarwal - IDFC Securities Ltd., Research Division

Anubhav Aggarwal - Crédit Suisse AG, Research Division

Abhay Shanbhag - Deutsche Bank AG, Research Division

Sameer Baisiwala - Morgan Stanley, Research Division

Prakash Agarwal - RBS Research

Bhagwan Singh Chaudhary - IndiaNivesh Securities Pvt Ltd., Research Division

Ranjit Kapadia - Centrum Broking Private Limited, Research Division

Ravi Agrawal - Standard Chartered plc, Research Division

Prashant Nair - Citigroup Inc, Research Division

Hitesh Mahida

Surajit Pal - Elara Securities (India) Private Limited, Research Division

Koushik Pal

Arvind Bothra - BofA Merrill Lynch, Research Division

Jorge Mauro

Rahul Sharma - KARVY Stock Broking Limited, Research Division



Ladies and gentlemen, good day, and welcome to the Q3 FY '12 Earnings Conference Call of Dr. Reddy's Laboratories Ltd. [Operator Instructions] Please note that this conference is being recorded. I would now like to hand the conference over to Mr. Kedar Upadhye. Thank you, and over to you, sir.

If you liked this article you might like

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: GLV, GLO, RDY